Bristol's $1.5 Billion Acquisition of Orbital Continues the Trend of 'In Vivo' Cell Therapy Agreements

Bristol’s $1.5 Billion Acquisition of Orbital Continues the Trend of ‘In Vivo’ Cell Therapy Agreements

Bristol's $1.5 Billion Acquisition of Orbital Continues the Trend of 'In Vivo' Cell Therapy Agreements